Table 2.
Clinical characteristics of patients with clinical failure and no clinical failure
| Characteristicsa | Clinical failure (n = 275) |
No clinical failure (n = 322) |
P value |
|---|---|---|---|
| Demographics and comorbid conditions present on admission | |||
| Mean age, years (± SD) | 59.9 (15.8) | 57.6 (16.2) | 0.079 |
| Age over 60, years | 126 (45.8) | 122 (37.9) | 0.050 |
| No. of male participants (%) | 178 (64.7) | 209 (64.9) | 0.963 |
| Admission from home | 189 (68.7) | 244 (75.7) | 0.054 |
| Admission from nursing | 66 (24.0) | 61 (18.9) | 0.132 |
| Transfer from outside institution | 20 (7.3) | 17 (5.2) | 0.314 |
| Primary BSI source | |||
| Pneumonia/other lower respiratory tract | 55 (20.0) | 51 (15.8) | 0.185 |
| Skin/soft tissue | 19 (6.9) | 60 (18.6) | < 0.001 |
| Infective endocarditis | 79 (28.7) | 37 (11.5) | < 0.001 |
| Central nervous system | 8 (2.9) | 4 (1.2) | 0.148 |
| Bone and joint | 52 (18.9) | 50 (15.5) | 0.274 |
| Prosthetic device | 21 (7.6) | 12 (3.7) | 0.037 |
| Urinary | 5 (1.8) | 8 (2.5) | 0.578 |
| Other or unknown | 45 (16.4) | 62 (19.3) | 0.359 |
| Comorbidity conditions, no. of patients (%) | |||
| Myocardial infarction | 19 (6.9) | 24 (7.5) | 0.798 |
| Heart failure | 62 (22.5) | 63 (19.6) | 0.372 |
| Chronic pulmonary diseaseb | 52 (18.9) | 67 (20.8) | 0.563 |
| Dementia | 31 (11.3) | 30 (9.3) | 0.432 |
| Diabetes | 112 (40.7) | 120 (37.3) | 0.388 |
| Peripheral vascular disease | 56 (20.4) | 54 (16.8) | 0.259 |
| CVA (stroke or TIA) | 40 (14.5) | 56 (17.4) | 0.345 |
| Moderate to severe CKDc | 109 (39.6) | 100 (31.1) | 0.028 |
| Chronic dialysis | 72 (26.2) | 79 (24.5) | 0.664 |
| HIV | 5 (1.8) | 15 (4.6) | 0.055 |
| Any immunosuppression | 13 (4.7) | 20 (6.2) | 0.429 |
| Liver disease | 41 (14.9) | 41 (12.7) | 0.441 |
| MRSA bacteremia risk factors, no. of patients (%) | |||
| Intravenous drug use | 57 (20.7) | 42 (13.0) | 0.012 |
| Prior hospitalization > 48 in preceding 90 days | 108 (39.3) | 120 (37.3) | 0.615 |
| Prior surgery 30 days preceding index culture | 16 (5.8) | 29 (9.0) | 0.141 |
| Prior MRSA infection ≤ 365 days preceding index culture | 48 (17.5) | 40 (12.4) | 0.084 |
| Prior antibiotics ≥ 24 in preceding 90 days | 94 (34.2) | 116 (36.0) | 0.618 |
| Severity of illness markers | |||
| APACHE II score, (± SD) | 19.29 (9.6) | 16.32 (8.3) | < 0.001 |
| ICU at index culture, n (%) | 49 (17.8) | 44 (13.7) | 0.163 |
| Charlson Comorbidity score, (± SD) | 3.26 (2.4) | 2.92 (2.3) | 0.087 |
| Daptomycin dose, mg | |||
| 6–8 mg per day | 37 (30.1) | 42 (31.1) | 0.927 |
| 8–10 mg per day | 42 (34.7) | 55 (40.7) | 0.321 |
| > 10 mg per day | 27 (22.3) | 28 (20.7) | 0.760 |
| Source control, no. of patients (%) | |||
| Removable source of infection | 121 (44.0) | 140 (43.5) | 0.893 |
| ID consult | 239 (86.9) | 281 (87.6) | 0.807 |
AIDS acquired immune deficiency virus, APACHE II acute physiology and chronic health evaluation II, BSI blood stream infection, CCI charlson comorbidity score, CNS central nervous system, ID infectious diseases, ICU intensive care unit, BSI bloodstream infection, MIC minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus, HIV acquired immunodeficiency syndrome
aAll values represent number (%) or median (interquartile range) as indicated
bAsthma and chronic obstructive pulmonary disease
cChronic kidney disease stages III–IV